Literature DB >> 15648030

Hyperphosphatemia and vascular calcification in end-stage renal disease.

Yoshiki Nishizawa1, Shuichi Jono, Eiji Ishimura, Atsushi Shioi.   

Abstract

Vascular calcification is a common finding in atherosclerosis and a serious problem in uremic patients. Because of the correlation of hyperphosphatemia and vascular calcification, the ability of extracellular inorganic phosphate levels to regulate human aortic smooth muscle cell (HSMC) culture mineralization in vitro was examined. HSMC cultured in media containing normal physiologic levels of inorganic phosphate (1.4 mM) did not mineralize. In contrast, HSMC cultured in media containing phosphate levels comparable with those seen in hyperphosphatemic individuals (>1.4 mM) showed dose-dependent increases in mineral deposition. Mechanistic studies showed that elevated phosphate treatment of HSMC also enhanced the expression of the osteoblastic differentiation markers osteocalcin and osf2/Cbfa-1. The effects of elevated phosphate on HSMC were mediated by a sodium-dependent phosphate cotransporter (NPC) as indicated by the ability of the specific NPC inhibitor phosphonoformic acid to dose-dependently inhibit phosphate-induced calcium deposition as well as osteocalcin and Cbfa-1 gene expression. The NPC in HSMC was identified as Pit-1, a member of the novel type III NPCs. These data suggest that elevated phosphate may directly stimulate HSMC to undergo phenotypic changes that predispose to calcification and offers a novel explanation of the phenomenon of vascular calcification under hyperphosphatemic conditions. Furthermore, we examined the factors affecting peripheral vascular calcification in 332 nondiabetic hemodialysis patients. There were 45 nondiabetic patients with vascular calcification. In multivariate logistic regression, the significant factors affecting vascular calcification were advanced age, longer duration of hemodialysis, increased phosphate concentrations, male gender, and lower predialysis diastolic pressure. Our findings suggest that an elevated phosphate level may directly stimulate HSMC to undergo phenotypic changes that predispose to calcification and offer a novel explanation of the phenomenon of vascular calcification under hyperphosphatemic conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15648030     DOI: 10.1053/j.jrn.2004.09.027

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  14 in total

1.  Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.

Authors:  M Inaba; S Okuno; Y Imanishi; S Yamada; A Shioi; T Yamakawa; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2006-08-05       Impact factor: 4.507

2.  Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients.

Authors:  Nazanin Noori; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Rachelle Bross; Debbie Benner; Joel D Kopple
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

3.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Authors:  Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 8.237

4.  Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice?

Authors:  Saso Gelev; Goce Spasovski; Sonja Dzikova; Zoran Trajkovski; Goge Damjanovski; Vili Amitov; Aleksandar Sikole
Journal:  Int Urol Nephrol       Date:  2008-06-27       Impact factor: 2.370

5.  Knowledge of phosphorus compared with other nutrients in maintenance dialysis patients.

Authors:  Judson B Pollock; Jonathan B Jaffery
Journal:  J Ren Nutr       Date:  2007-09       Impact factor: 3.655

6.  Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis.

Authors:  Fumiko Kojima; Keiko Uchida; Tetsuya Ogawa; Yoshiko Tanaka; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2008-09-13       Impact factor: 2.370

7.  Valvular endothelial cells and the mechanoregulation of valvular pathology.

Authors:  Jonathan T Butcher; Robert M Nerem
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

Review 8.  Calcific uremic arteriolopathy in end stage renal disease: pathophysiology and management.

Authors:  Preethi Yerram; Kunal Chaudhary
Journal:  Ochsner J       Date:  2014

Review 9.  A review of the effect of diet on cardiovascular calcification.

Authors:  Rachel Nicoll; John McLaren Howard; Michael Y Henein
Journal:  Int J Mol Sci       Date:  2015-04-21       Impact factor: 5.923

10.  Smooth Muscle-Selective Nuclear Factor-κB Inhibition Reduces Phosphate-Induced Arterial Medial Calcification in Mice With Chronic Kidney Disease.

Authors:  Tadashi Yoshida; Maho Yamashita; Chihiro Horimai; Matsuhiko Hayashi
Journal:  J Am Heart Assoc       Date:  2017-11-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.